Semantic Scholar uses AI to extract papers important to this topic.
Pasireotide (SOM230) is a novel multireceptor-targeted somatostatin (sst) analog with high binding affinity for sst receptor… Expand Background The discovery of somatostatin (SST) and the synthesis of a variety of analogues constituted a major therapeutic… Expand CONTEXT
There is currently no medical therapy for Cushing's disease that targets the pituitary adenoma. Availability of such a… Expand Pasireotide (SOM230) is a multi-receptor ligand somatostatin analogue with high binding affinity for somatostatin receptor… Expand CONTEXT
There is no tumor-directed medical therapy available for Cushing's disease.
The objective was to determine… Expand In a series of human corticotroph adenomas, we recently found predominant mRNA expression of somatostatin (SS) receptor subtype 5… Expand OBJECTIVE
Currently, there is no effective medical treatment for patients with pituitary-dependent Cushing's disease. A novel… Expand To determine the inhibitory profile of the novel somatostatin (SRIF) analog SOM230 with broad SRIF receptor binding, we compared… Expand Functional gastroenteropancreatic tumors express all 5 somatostatin receptor subtypes (sst) in different quantities. Octreotide… Expand OBJECTIVE
The aim of the present study was to identify a small, metabolically stable somatotropin release inhibiting factor (SRIF… Expand